144 related articles for article (PubMed ID: 7874767)
1. [P21 expression of ras oncogene product in benign and malignant female mammary lesions].
Zhang JZ; Fan SC; Liu HF
Zhonghua Bing Li Xue Za Zhi; 1994 Oct; 23(5):302-3. PubMed ID: 7874767
[TBL] [Abstract][Full Text] [Related]
2. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-kit in common benign and malignant breast lesions.
Kondi-Pafiti A; Arkadopoulos N; Gennatas C; Michalaki V; Frangou-Plegmenou M; Chatzipantelis P
Tumori; 2010; 96(6):978-84. PubMed ID: 21388062
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
Zheng WQ; Looi LM; Cheah PL
Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
[TBL] [Abstract][Full Text] [Related]
5. Lectin binding patterns in benign and malignant lesions of the breast.
Karuna V; Shanthi P; Madhavan M
Indian J Pathol Microbiol; 1992 Oct; 35(4):289-97. PubMed ID: 1344218
[TBL] [Abstract][Full Text] [Related]
6. P53 expression in patients with malignant and benign breast diseases.
Kalogeraki A; Panayiotides J; Tamiolakis D; Tzardi M; Chaniotis V; Chalkiadakis G; Melissas J; Stiftsis D; Kanavaros P; Delides GS
Anticancer Res; 2000; 20(3A):1801-5. PubMed ID: 10928110
[TBL] [Abstract][Full Text] [Related]
7. p53 protein expression in benign and malignant breast lesions.
Ioakim-Liossi A; Markopoulos C; Karakitsos P; Safioleas M; Gogas J; Vaiopoulos G
Acta Cytol; 1998; 42(4):918-22. PubMed ID: 9684577
[TBL] [Abstract][Full Text] [Related]
8. The phosphorylated form of connexin43 is up-regulated in breast hyperplasias and carcinomas and in their neoformed capillaries.
Gould VE; Mosquera JM; Leykauf K; Gattuso P; Dürst M; Alonso A
Hum Pathol; 2005 May; 36(5):536-45. PubMed ID: 15948121
[TBL] [Abstract][Full Text] [Related]
9. Proliferating cell nuclear antigen (PCNA) expression in patients with breast carcinoma in comparison to patients with benign breast diseases.
Kalogeraki A; Tzardi M; Datseris G; Kanavaros P; Karvelas C; Chalkiadakis G; Tsiftsis D; Delides G
In Vivo; 1994; 8(6):1053-6. PubMed ID: 7772736
[TBL] [Abstract][Full Text] [Related]
10. Localization of mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase type II in human breast and its disorders.
Sasano H; Frost AR; Saitoh R; Matsunaga G; Nagura H; Krozowski ZS; Silverberg SG
Anticancer Res; 1997; 17(3C):2001-7. PubMed ID: 9216657
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status.
Tsuura Y; Suzuki T; Honma K; Sano M
J Cancer Res Clin Oncol; 2002 May; 128(5):239-46. PubMed ID: 12029439
[TBL] [Abstract][Full Text] [Related]
12. Expression of hyaluronan in benign and malignant breast lesions.
Auvinen PK; Parkkinen JJ; Johansson RT; Agren UM; Tammi RH; Eskelinen MJ; Kosma VM
Int J Cancer; 1997 Oct; 74(5):477-81. PubMed ID: 9355968
[TBL] [Abstract][Full Text] [Related]
13. Consistent lack of CD34-positive stromal cells in the stroma of malignant breast lesions.
Kuroda N; Jin YL; Hamauzu T; Toi M; Miyazaki E; Hiroi M; Moriki T; Enzan H
Histol Histopathol; 2005 Jul; 20(3):707-12. PubMed ID: 15944918
[TBL] [Abstract][Full Text] [Related]
14. [Methodological approaches to quantitative immunohistochemical evaluation of expression of breast apoptosis and proliferation markers].
Kostiuchek IN; Kogan IIu; Kvetnoĭ IM
Arkh Patol; 2006; 68(1):47-8. PubMed ID: 16544540
[TBL] [Abstract][Full Text] [Related]
15. Altered mucin expression is a field change that accompanies mucinous (colloid) breast carcinoma histogenesis.
O'Connell JT; Shao ZM; Drori E; Basbaum CB; Barsky SH
Hum Pathol; 1998 Dec; 29(12):1517-23. PubMed ID: 9865841
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of E-cadherin in sclerosing adenosis, ductal carcinoma in situ and invasive ductal carcinoma of the breast.
Facina G; Lopes-Costa PV; Dos Santos AR; De Vasconcelos-Valença RJ; Pinho-Sobral AL; Ferreira-Filho CP; Alencar AP; Gebrim LH; Da Silva BB
Diagn Cytopathol; 2010 Apr; 38(4):235-8. PubMed ID: 19790246
[TBL] [Abstract][Full Text] [Related]
17. Expression of c-erbB-2 oncogene and p53 tumor suppressor gene in benign and malignant breast tissue: correlation with proliferative activity and prognostic index.
Alexiev BA; Bassarova AV; Popovska SL; Popov AA; Christov CZ
Gen Diagn Pathol; 1997 Jun; 142(5-6):271-9. PubMed ID: 9228249
[TBL] [Abstract][Full Text] [Related]
18. The neurofibromin 1 type I isoform predominance characterises female population affected by sporadic breast cancer: preliminary data.
Marrero D; Peralta R; Valdivia A; De la Mora A; Romero P; Parra M; Mendoza N; Mendoza M; Rodriguez D; Camacho E; Duarte A; Castelazo G; Vanegas E; Garcia I; Vargas C; Arenas D; Jimenez F; Salcedo M
J Clin Pathol; 2012 May; 65(5):419-23. PubMed ID: 22412049
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated overexpression of the soluble T1-S receptor in lymph node-negative breast cancer.
Werenskiold AK; Prechtel D; Harbeck N; Höfler H
Diagn Mol Pathol; 2000 Mar; 9(1):26-34. PubMed ID: 10718210
[TBL] [Abstract][Full Text] [Related]
20. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
